<DOC>
	<DOCNO>NCT01614886</DOCNO>
	<brief_summary>To evaluate tolerability , safety efficacy 3-step titration versus 1-step titration Rivastigmine patch Japanese population .</brief_summary>
	<brief_title>Randomized , Double-blind Study Evaluate Tolerability 2 Different Titration Methods Rivastigmine Patch AD Patients ( MMSE 10-20 )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>A diagnosis dementia Alzheimer 's type accord DSMIV criterion A clinical diagnosis probable AD accord NINCDS/ADRDA criterion An MMSE score ≥ 10 ≤ 20 baseline Any medical neurological condition AD could explain patient 's dementia A current diagnosis probable possible vascular dementia A score &gt; 5 Modified Hachinski Ischemic Scale ( MHIS ) A current DSMIV Axis 1 diagnosis may interfere evaluation patient 's response study medication . Treated donepezil galantamine within last 4 week efficacy assessment baseline . advance severe progressive unstable disease type may interfere efficacy safety assessment put patient 's special risk Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Rivastigmine , Alzheimer 's disease , Transdermal patch</keyword>
</DOC>